How to Get Mounjaro Online in 2026
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Telehealth providers can prescribe it for on-label use, while Zepbound contains the same active ingredient and is approved for weight management.
Mounjaro is a once-weekly tirzepatide injection FDA-approved for type 2 diabetes.
Adults with type 2 diabetes seeking dual GIP/GLP-1 receptor agonist glycemic control.
KwikPen and pen formats available. Monthly cost without insurance typically $1,000-$1,200.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
Providers That Prescribe Mounjaro
Board-certified primary-care telehealth with the widest brand-name GLP-1 access in this list.
Full-spectrum GLP-1 program with both compounded and brand-name access plus unlimited provider check-ins.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Personalised, physician-endorsed longevity and weight-loss therapies, fully online.
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Personalised GLP-1 and sexual-wellness program with insurance navigation and optional nutrition coaching.
Medically supervised, discreet, multi-category telehealth with a heavy compounded formulary.
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
What the Studies Actually Show
Mounjaro is FDA-approved tirzepatide for type 2 diabetes. The evidence below comes from the SURPASS program (registration trials), the SURMOUNT obesity program (relevant to expected weight effects in patients with T2D), and the FDA prescribing information.
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| GI side effects (FDA prescribing information)4 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5% |
| Boxed warning4 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SURPASS program)5 | ≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5 |
| Compounded tirzepatide — evidence basis6 | Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products |
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.